822.5500 -4.50 (-0.54%)
NSE Jul 16, 2025 15:31 PM
Volume: 969.0K
 

logo
Laurus Labs Ltd.
04 Aug 2018
822.55
-0.54%
Motilal Oswal
4 August 2018 revenue came in at INR5.3b (our estimate of INR5.5b), up 9.7% YoY. The ARV segment (69% of sales) grew 37% YoY and the Synthesis segment (10% of sales) grew 65% YoY, driving its overall revenue growth for the quarter. A decline of 69% YoY in the Hep-C business (5% of sales) and 45% YoY in other API (4% of sales), coupled with flat sales YoY of the Oncology segment (8% of sales) pulled down the overall revenue growth. This coupled with increased depreciation and interest cost led to a decline of 58% YoY in PAT to INR165m (our estimate of INR448m). We cut our EPS estimates by 23%/9% for FY19/FY20 to INR21/INR31 to factor in the increased raw material cost for 1HFY19 and delay in pick-up of the formulation business. Accordingly, we value LAURUS at 18x FY20E EPS of INR31 and arrive at a price target of INR552.
Laurus Labs Ltd. has gained 47.70% in the last 6 Months
More from Laurus Labs Ltd.
Recommended